We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
THE INCIDENCE, CLINICAL APPLICATION AND PROGNOSTIC SIGNIFICANCE OF MYD88 AND CXCR4 MUTATION IN CHINESE PATIENTS WITH LYMPHOPLASMACYTIC LYMPHOMA/WALDENSTRöM MACROGLOBULINEMIA.
- Authors
Yu, Y.; Yan, Y.; Wang, J.; Xiong, W.; Yao, Y.; Huang, Y.; Lyu, R.; Wang, T.; Wang, Q.; Liu, W.; An, G.; Sui, W.; Xiao, Z.; Xu, Y.; Huang, W.; Zou, D.; Qiu, L.; Yi, S.
- Abstract
CXCR4 mutation testing was performed in 358 patients of LPL/WM, comprising 301 with FGS, 236 with NGS, and 311 with ASPCR. Patients with CXCR4 mutation tended to be older (median 64 vs. 60, I p i < 0.001) and displayed lower hemoglobin level (median 81 g/L vs. 93 g/L, I p i = 0.008), higher serum IgM level (median 36.1 g/L vs. 31.6 g/L, I p i < 0.001), and higher baseline BM involvement (by FCM, median 15.1% vs. 7.1%, I p i < 0.001) compared with CXCR4 wild-type patients. B Introduction: b Waldenström macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL) is a rare, B-cell lymphoma with highly prevalent somatic mutations including MYD88, and CXCR4.
- Subjects
WALDENSTROM'S macroglobulinemia; CXCR4 receptors; CHINESE people; MYELOID differentiation factor 88; CLINICAL medicine
- Publication
Hematological Oncology, 2023, Vol 41, p656
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3165_508